In vivo imaging of trypanosomes for a better assessment of host-parasite relationships and drug efficacy

Parasitology International

Volumn 63, Issue 1, 2014, Pages 260-268

  Goyard, S ^a   Dutra, P Lourenço ^a,b   Deolindo, P ^a,c   Autheman, D ^a   D'Archivio, S ^a   Minoprio, P ^a  

^a INSTITUT PASTEUR   (France)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Bioluminescent imaging; E2 Crimson; Firefly luciferase; GFP; In vivo imaging; Trypanosoma cruzi; Trypanosoma vivax

Indexed keywords

ETHIDIUM BROMIDE; NEOMYCIN; PAROMOMYCIN; NEW DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFICACY; EPIMASTIGOTE; FLUORESCENCE IMAGING; GENETIC TRANSFECTION; HOST CELL; HOST PARASITE INTERACTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARASITE SURVIVAL; PRIORITY JOURNAL; TRYPANOSOMA CRUZI; TRYPANOSOMA VIVAX; ANIMAL CELL; CONTROLLED STUDY; DISEASE COURSE; DRUG SCREENING; GENE EXPRESSION; HOST; HUMAN; KINETOPLASTIDA; PROTEIN LOCALIZATION; REPORTER GENE;

MURINAE; TRYPANOSOMA CRUZI; TRYPANOSOMA VIVAX; TRYPANOSOMATIDAE;

BIOLUMINESCENT IMAGING; E2-CRIMSON; FIREFLY LUCIFERASE; GFP; IN VIVO IMAGING; TRYPANOSOMA CRUZI; TRYPANOSOMA VIVAX;

ANIMALS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LUCIFERASES, FIREFLY; LUMINESCENT MEASUREMENTS; MALE; MICE; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI; TRYPANOSOMA VIVAX;

EID: 84888132089     PISSN: 13835769     EISSN: 18730329     Source Type: Journal    
DOI: 10.1016/j.parint.2013.07.011     Document Type: Article

References (48)

1. World-Health-Organisation Working to overcome the global impact of neglected tropical diseases 2010, WHO, Geneva, Switzerland, [1 1].
2. Lebowitz J.H., Coburn C.M., Beverley S.M. Simultaneous transient expression assays of the trypanosomatid parasite Leishmania using beta-galactosidase and beta-glucuronidase as reporter enzymes. Gene 1991, 103:119-123.
3. Sommer J.M., Cheng Q.L., Keller G.A., Wang C.C. In vivo import of firefly luciferase into the glycosomes of Trypanosoma brucei and mutational analysis of the C-terminal targeting signal. Molecular Biology of the Cell 1992, 3:749-759.
4. Ha D.S., Schwarz J.K., Turco S.J., Beverley S.M. Use of the green fluorescent protein as a marker in transfected Leishmania. Molecular and Biochemical Parasitology 1996, 77:57-64.
5. dos Santos W.G., Buck G.A. Simultaneous stable expression of neomycin phosphotransferase and green fluorescence protein genes in Trypanosoma cruzi. Journal of Parasitology 2000, 86:1281-1288.
6. Pires S.F., DaRocha W.D., Freitas J.M., Oliveira L.A., Kitten G.T., Machado C.R., et al. Cell culture and animal infection with distinct Trypanosoma cruzi strains expressing red and green fluorescent proteins. International Journal for Parasitology 2008, 38:289-297.
7. Hyland K.V., Asfaw S.H., Olson C.L., Daniels M.D., Engman D.M. Bioluminescent imaging of Trypanosoma cruzi infection. International Journal of Parasitology 2008, 38:1391-1400.
8. Giroud C., Ottones F., Coustou V., Dacheux D., Biteau N., Miezan B., et al. Murine models for Trypanosoma brucei gambiense disease progression-from silent to chronic infections and early brain tropism. PLoS Neglected Tropical Diseases 2009, 3:e509.
9. D'Archivio S., Cosson A., Medina M., Lang T., Minoprio P., Goyard S. Non-invasive in vivo study of the Trypanosoma vivax infectious process consolidates the brain commitment in late infections. PLoS Neglected Tropical Diseases 2013, 7:e1976.
10. Frevert U., Movila A., Nikolskaia O.V., Raper J., Mackey Z.B., Abdulla M., et al. Early invasion of brain parenchyma by African trypanosomes. PLoS One 2012, 7:e43913.
11. Claes F., Vodnala S.K., van Reet N., Boucher N., Lunden-Miguel H., Baltz T., et al. Bioluminescent imaging of Trypanosoma brucei shows preferential testis dissemination which may hamper drug efficacy in sleeping sickness. PLoS Neglected Tropical Diseases 2009, 3:e486.
12. Close D.M., Xu T., Sayler G.S., Ripp S. In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals. Sensors (Basel) 2011, 11:180-206.
13. Plock A., Sokolowska-Kohler W., Presber W. Application of flow cytometry and microscopical methods to characterize the effect of herbal drugs on Leishmania spp. Experimental Parasitology 2001, 97:141-153.
14. Dube A., Gupta R., Singh N. Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends in Parasitology 2009, 25:432-439.
15. Okuno T., Goto Y., Matsumoto Y., Otsuka H., Matsumoto Y. Applications of recombinant Leishmania amazonensis expressing EGFP or the beta-galactosidase gene for drug screening and histopathological analysis. Experimental Animals 2003, 52:109-118.
16. Lang T., Goyard S., Lebastard M., Milon G. Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cellular Microbiology 2005, 7:383-392.
17. Canavaci A.M., Bustamante J.M., Padilla A.M., Perez Brandan C.M., Simpson L.J., Xu D., et al. In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Neglected Tropical Diseases 2010, 4:e740.
18. Leeflang P., Buys J., Blotkamp C. Studies on Trypanosoma vivax: infectivity and serial maintenance of natural bovine isolates in mice. International Journal of Parasitology 1976, 6:413-417.
19. Chamond N., Cosson A., Blom-Potar M.C., Jouvion G., D'Archivio S., Medina M., et al. Trypanosoma vivax infections: pushing ahead with mouse models for the study of Nagana. I. Parasitological, hematological and pathological parameters. PLoS Neglected Tropical Diseases 2010, 4:e792.
20. D'Archivio S., Medina M., Cosson A., Chamond N., Rotureau B., Minoprio P., et al. Genetic engineering of Trypanosoma (Dutonella) vivax and in vitro differentiation under axenic conditions. PLoS Neglected Tropical Diseases 2011, 5:e1461.
21. de Sousa M.A. A simple method to purify biologically and antigenically preserved bloodstream trypomastigotes of Trypanosoma cruzi using DEAE-cellulose columns. Memórias do Instituto Oswaldo Cruz 1983, 78:317-333.
22. Brener Z. Biology of Trypanosoma cruzi. Annual Review of Microbiology 1973, 27:347-382.
23. Hirumi H., Hirumi K., Moloo S.K., Shaw M.K. Trypanosoma brucei brucei: in vitro production of metacyclic forms. Journal of Protozoology 1992, 39:619-627.
24. Strack R.L., Hein B., Bhattacharyya D., Hell S.W., Keenan R.J., Glick B.S. A rapidly maturing far-red derivative of DsRed-Express2 for whole-cell labeling. Biochemistry 2009, 48:8279-8281.
25. Guevara P., Dias M., Rojas A., Crisante G., Abreu-Blanco M.T., Umezawa E., et al. Expression of fluorescent genes in Trypanosoma cruzi and Trypanosoma rangeli (Kinetoplastida: Trypanosomatidae): its application to parasite-vector biology. Journal of Medical Entomology 2005, 42:48-56.
26. Strack R.L., Bhattacharyya D., Glick B.S., Keenan R.J. Noncytotoxic orange and red/green derivatives of DsRed-Express2 for whole-cell labeling. BMC Biotechnology 2009, 9:32.
27. Berneman A., Montout L., Goyard S., Chamond N., Cosson A., d'Archivio S., et al. Combined approaches for drug design points the way to novel proline racemase inhibitor candidates to fight chagas' disease. PLoS One 2013, 8:e60955.
28. Minoprio P., Itohara S., Heusser C., Tonegawa S., Coutinho A. Immunobiology of murine T. cruzi infection: the predominance of parasite-nonspecific responses and the activation of TcRI T cells. Immunological Reviews 1989, 112:183-207.
29. Reina-San-Martin B., Cosson A., Minoprio P. Lymphocyte polyclonal activation: a pitfall for vaccine design against infectious agents. Parasitology Today 2000, 16:62-67.
30. Santos Lima E.C., Garcia I., Vicentelli M.H., Vassalli P., Minoprio P. Evidence for a protective role of tumor necrosis factor in the acute phase of Trypanosoma cruzi infection in mice. Infection and Immunity 1997, 65:457-465.
31. Santos Lima E.C., Minoprio P. Chagas' disease is attenuated in mice lacking gamma delta T cells. Infection and Immunity 1996, 64:215-221.
32. Cordeiro da Silva A., Lima E.C., Vicentelli M.H., Minoprio P. V beta 6-bearing T cells are involved in resistance to Trypanosoma cruzi infection in XID mice. International Immunology 1996, 8:1213-1219.
33. Reina-San-Martin B., Degrave W., Rougeot C., Cosson A., Chamond N., Cordeiro-Da-Silva A., et al. A B-cell mitogen from a pathogenic trypanosome is a eukaryotic proline racemase. Nature Medicine 2000, 6:890-897.
34. Chamond N., Goytia M., Coatnoan N., Barale J.C., Cosson A., Degrave W.M., et al. Trypanosoma cruzi proline racemases are involved in parasite differentiation and infectivity. Molecular Microbiology 2005, 58:46-60.
35. Weston D., La Flamme A.C., Van Voorhis W.C. Expression of Trypanosoma cruzi surface antigen FL-160 is controlled by elements in the 3' untranslated, the 3' intergenic, and the coding regions. Molecular and Biochemical Parasitology 1999, 102:53-66.
36. Lorenzi H.A., Vazquez M.P., Levin M.J. Integration of expression vectors into the ribosomal locus of Trypanosoma cruzi. Gene 2003, 310:91-99.
37. Henriques C., Castro D.P., Gomes L.H., Garcia E.S., de Souza W. Bioluminescent imaging of Trypanosoma cruzi infection in Rhodnius prolixus. Parasites & Vectors 2012, 5:214.
38. Balmer O., Tostado C. New fluorescence markers to distinguish co-infecting Trypanosoma brucei strains in experimental multiple infections. Acta Tropica 2006, 97:94-101.
39. Mehta S.R., Huang R., Yang M., Zhang X.Q., Kolli B., Chang K.P., et al. Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery. Clinical and Vaccine Immunology 2008, 15:1764-1770.
40. Pulido S.A., Munoz D.L., Restrepo A.M., Mesa C.V., Alzate J.F., Velez I.D., et al. Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs. Acta Tropica 2012, 122:36-45.
41. Conti P., Tamborini L., Pinto A., Blondel A., Minoprio P., Mozzarelli A., et al. Drug discovery targeting amino acid racemases. Chemical Reviews 2011, 111:6919-6946.
42. Esperandim V.R., da Silva Ferreira D., Toldo M.P., Saraiva J., Augusto M.B., de Albuquerque S. New method for quantification of Trypanosoma cruzi in animal's tissue in the chronic phase of experimental Chagas' disease. Parasitology Research 2010, 106:1471-1473.
43. Faust N., Varas F., Kelly L.M., Heck S., Graf T. Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. Blood 2000, 96:719-726.
44. Ovchinnikov D.A., van Zuylen W.J., DeBats C.E., Alexander K.A., Kellie S., Hume D.A. Expression of Gal4-dependent transgenes in cells of the mononuclear phagocyte system labeled with enhanced cyan fluorescent protein using Csf1r-Gal4VP16/UAS-ECFP double-transgenic mice. Journal of Leukocyte Biology 2008, 83:430-433.
45. Sasmono R.T., Oceandy D., Pollard J.W., Tong W., Pavli P., Wainwright B.J., et al. A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood 2003, 101:1155-1163.
46. Stepanenko O.V., Stepanenko O.V., Shcherbakova D.M., Kuznetsova I.M., Turoverov K.K., Verkhusha V.V. Modern fluorescent proteins: from chromophore formation to novel intracellular applications. Biotechniques 2011, 51:313-314. [6, 8 passim].
47. Stepanenko O.V., Verkhusha V.V., Kazakov V.I., Shavlovsky M.M., Kuznetsova I.M., Uversky V.N., et al. Comparative studies on the structure and stability of fluorescent proteins EGFP, zFP506, mRFP1, "dimer2", and DsRed1. Biochemistry 2004, 43:14913-14923.
48. Buckers J., Wildanger D., Vicidomini G., Kastrup L., Hell S.W. Simultaneous multi-lifetime multi-color STED imaging for colocalization analyses. Optics Express 2011, 19:3130-3143.